London, United Kingdom Engineering and Design practice group

"They have expertise in the fields we need assistance in."

(Client comment - Client satisfaction survey)

With a heritage stretching back to 1894, Boult Wade Tennant has long been regarded as a quality firm producing quality work. As a firm, we nurture attorneys with exceptional technical skills, a wealth of legal experience and a depth of commercial awareness. These assets combine to provide our clients with a real advantage. You only have to look at the recent reviews and league tables to see that this is a view shared by our clients and peers alike.

We place an emphasis not only on the quality of our work, but also on the quality of the service we provide to our clients. Always approachable, down-to-earth and jargon-free, it is our aim to work with you, not just for you. By getting to know you and your business, we can offer practical solutions to the problems you face. “Partnership” and “team work” are more than just words. They are part of who we are: enthusiastic team players, equipped with the necessary technical, legal and commercial knowledge that allows us to partner you in whatever may lie ahead.

News and information

Dr Nina White appointed member of CIPA's Life Sciences Committee

Boult Wade Tennant Partner Nina White has recently been appointed to the Chartered Institute of Patent Attorneys (CIPA)’s Life Sciences Committee, of which Senior Partner Claire Baldock was a long-serving and valued member until she stepped down earlier this month.  Read more

Boult Wade Tennant’s patent practice tops the MIP rankings once again

Managing Intellectual Property (MIP) has ranked the firm’s patent practice in the top tier of its annual survey for the tenth year running.  Read more

English Patents Court Judgement provides much needed guidance on the scope of second medical use claims

In an important judgement for the interpretation of second medical use claims in the UK, Mr Justice Arnold refused a request by Warner Lambert for an interim injunction against Actavis in relation to its plans to launch a generic version of the drug pregabalin  Read more